Skip to main
  1. Stocks
  2. Gossamer Bio Inc
  3. Forecast
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is well positioned by seralutinib, whose late September NDA submission for PAH is supported by PROSERA and TORREY data, including a +13.3 m placebo-adjusted 6MWD benefit and a safety profile viewed as manageable in a high-unmet-need disease. The FDA has framed the statistical significance and effect size as a review issue rather than a filing barrier, while the company expects a standard review and is preparing for commercialization within ~one-year after re-acquiring worldwide rights in July 2026. Financially, Gossamer Bio ended 3Q26 with $51.2M in cash, and milestone-linked financing could add $125M upon NDA acceptance and $100M upon approval, while management still sees $2B+ peak sales potential worldwide.

Bears say

Gossamer Bio is viewed negatively because seralutinib, the main value driver, faces substantial regulatory risk after PROSERA missed its prespecified primary endpoint, leaving FDA free to demand another controlled study, issue a Complete Response Letter, or approve only a narrower label. The efficacy package is also vulnerable, as the +13.3 m placebo-adjusted 6MWD gain in the ITT population is modest, the subgroup strength may be seen as too narrow, and safety concerns persist with discontinuations at 15.0% versus 5.8% and adverse events of special interest at 20.5% versus 6.3%. Even if approved, commercial execution is uncertain in an increasingly competitive PAH market where it would likely be a third or later agent, while Chiesi’s exit leaves Gossamer responsible for development, launch, and potentially dilutive financing needs.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

GOSS Analyst Forecast & Price Prediction

Get the latest GOSS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GOSS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


GOSS Analyst Forecast & Price Prediction

Get the latest GOSS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GOSS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GOSS stock data and trends